**FIGURE 1A**

An effective dose of a pharmaceutically acceptable phenylbutyrate salt such as sodium phenylbutyrate applied to human ocular tissues or through injection or other means prevents ocular hypertension and treats glaucoma in humans. This compound can be formulated in combination with topical or other forms of steroids in prevention and treatment of steroid induced ocular hypertension and glaucoma.
METHOD AND MEDICATION FOR PREVENTION AND TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA

BACKGROUND OF THE INVENTION

This invention relates to the prevention and treatment of ocular diseases and in particular ocular hypertension and glaucoma. Glaucoma is a leading cause of irreversible blindness worldwide. Loss of visual function is considered inevitable with progressive degeneration of the optic nerve.

The number of patients worldwide is expected to be increasing with aging population. It was estimated that there were 60.5 million glaucoma patients in 2010, increasing to 79.6 million by 2020 with 21.8 millions in China. A considerable proportion of patients with ocular hypertension and glaucoma fail to have optimal control of intraocular pressure. These patients often require surgical intervention which may end up with undesirable visual outcome. There is a need for a new class of medication for lowering as well as preventing intraocular pressure rise in susceptible individuals.

All current forms of glaucoma medical treatment are targeted at lowering the intraocular pressure. (Sit 2008; Singh, 2008) These include sympathetic nerve stimulants (nonselective stimulants such as epinephrine and alpha2 stimulants such as apraclonidine), sympathetic nerve blockers (beta blockers including timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol, and metipranolol and alphal blockers such as bunazosin hydrochloride), parasympathetic nerve agonists (pilocarpine), carbonic anhydrase inhibitors (acetazolamide and dorzolamide), and prostaglandin analogue (isopropyl unoprostone, latanoprost, travoprost, bimatoprost). These drugs either decrease the production of aqueous humor or increase the outflow facility through the trabecular meshwork and/or the uveoscleral outflow channels.

While aging, the use of topical steroids, myopia and a family medical history of glaucoma have been recognized as risk factors, lowering the intraocular pressure (IOP) remains the most effective approach in preventing visual loss in the glaucoma continuum. Although the pathologic mechanism for the development of glaucoma is not fully understood, it has been suggested that mutations in the myocilin gene (Jacobson, 2011; Jia 2009; Yam, 2007b), which may lead to an accumulation of defective myocilin gene product, might be a
factor in a small subset that accounts for 2-4% of all the glaucoma patients (Alward, 1998; Fingert, 1999). If the above mechanism is correct, chaperones that reduce myocilin accumulation may be useful for this small group of patients. In reality, as most patients with glaucoma do not have a defective myocilin gene, this approach will be rendered inapplicable.

Sodium phenylbutyrate, (more specifically, a salt of 4-phenylbutyrate with structure shown in Figure 1A), is a medication that has been used clinically to treat urea cycle disorders, sickle cell anemia and β-thalassemia (Brusilow, 1996; Collins, 1995; Dover, 1994).

Sodium phenylbutyrate is a short-chain fatty acid (Figure 1B) and its chaperone effect has previously been shown to stabilize myocilin folding and facilitate intracellular trafficking and therefore reduce abnormal protein accumulation in cells that would lead to cell stress and death. (Yam, 2007a) It is therefore possible that patients with mutated myocilin gene defect can get beneficial effect from receiving sodium phenylbutyrate treatment. Oral administration of sodium phenylbutyrate has been shown very recently to rescue glaucoma phenotypes in mice expressing Y437H mutant myocilin transgene with normalization of elevated intraocular pressure when compared to untreated transgene mice (Zode et al., Association for Research in Vision and Ophthalmology 2011 Annual Meeting Abstract). Nonetheless, one would predict that this compound would have no effect on animals or patients with normal myocilin gene. As hereinafter shown, the opposite is true.

By way of support for the present invention but not as prior act, we found that sodium phenylbutyrate is effective in preventing and treating the intraocular pressure rise in an animal model of steroid-induced glaucoma in normal rabbits. (Figures 2A and 2B and Figure 3). Such an animal model is commonly used for glaucoma research.

Moreover, if sodium phenylbutyrate is using its chaperone effect in preventing and treating the intraocular pressure rise in rabbits, one might predict that other chaperones may also work to lower the intraocular pressure. To explore this hypothesis, trimethylamine N-oxide (TMAO) was tested out using the same steroid-induced glaucoma model in rabbits. TMAO is another well known small-molecule chaperone (Gong, 2009; Kolter, 2003; Perlmutter, 2002); a natural osmolyte capable of stabilizing protein folding and acting as a protein stabilizer to protect ligand binding and polymerization against pressure inhibition. It improves folding and assembly of different proteins. Surprisingly, we found that TMAO was not effective at all in reducing the intraocular pressure rise as shown in the case of sodium phenylbutyrate. Specifically Figure 4 illustrates the negative effect of trimethylamine N-oxide (TMAO) on dexamethasone-induced intraocular pressure changes. Fourteen New
Zealand albino rabbits (7-week-old male) were divided into 5 groups. The right eyes received topical dexamethasone four times a day followed by topical TMAO (2, 10, 50, 100 and 300 mM) four times a day whereas the left eyes received topical dexamethasone four times a day followed by balanced salt solution, a physiological saline that acted as a control, four times a day. Topical TMAO did not prevent or treat the dexamethasone-induced intraocular pressure rise for the entire study period of 18 days (Figure 4). The intraocular pressure in both eyes showed no significant difference. This suggests that prevention and treatment of elevation of steroid-induced intraocular pressure by sodium phenylbutyrate may not be related to chemical chaperone activity. This finding is very surprising.

[0009] The following references are pertinent to this disclosure:


SUMMARY OF THE INVENTION

[0010] According to the invention, a medication is provided for use in treating a disease that comprises an effective dose of a pharmaceutically acceptable salt of phenylbutyrate, and particularly sodium phenylbutyrate, in an appropriate solution or carrier, such as an ophthalmic solution, salve or cream. In use the solution or carrier is topically applied to ocular tissue or through periocular (including subconjunctival, subtenon, peribulbar, retrobulbar, and anterior juxtascleral depot), intraocular (intracameral and intravitreal), systemic intake (oral ingestion and parenteral injection), or via controlled or sustained release methods or other means, prevents ocular hypertension and treats glaucoma in humans, leading to a new medical therapy for lowering the intraocular pressure via a mechanism different from the existing glaucoma medications. This compound can be formulated or modified in combination with an anti-inflammatory steroid, a steroid prodrug or a cortisol-derived compound of different formulations and/or other currently available glaucoma medications in prevention and treatment of steroid induced ocular hypertension and glaucoma.

[0011] While we have shown that prevention and treatment of elevation of steroid-induced intraocular pressure by sodium phenylbutyrate is mostly likely not related to its chemical chaperone activity, we do not know the exact mechanism(s). It is possible that other activities of sodium phenylbutyrate including its effect on histone acetylation (acetylation), transcriptions and protein prenylation, and nitrogen scavenger activities are responsible for the intraocular pressure lowering effect herein reported.

[0012] There were four more surprising findings from experiments:

[0013] First, sodium phenylbutyrate was found to be useful for the prevention of steroid-induced intraocular pressure rise (Figure 2).
Second, sodium phenylbutyrate was effective for lowering intraocular pressure in steroid-induced glaucoma (Figure 3).

Third, the doses effective in and useful for reducing the increase of steroid-induced intraocular pressure were found to be extremely low, surprisingly much lower than the dose used for the treatment of urea cycle disorders, in which the chaperone effect is believed to be the therapeutic mechanism. In our animal experiments, the level of sodium phenylbutyrate was found to be effective with concentrations as low as 0.01 to 15 mM when applied 2-5 times a day (Figures 5 and 6).

Fourth, the pharmacodynamic effect was found to be extremely long-lasting, which is out of one's expectation. We found that topical sodium phenylbutyrate was able to suppress the intraocular pressure rise for a maximum of 18 days after the cessation of applications of the sodium phenylbutyrate eyedrops (Figure 7).

The invention will be better understood by reference to the following detailed description in connection with the accompanying drawings.

BRIEF DESCRIPTIONS OF THE DRAWINGS

Figures 1A and 1B are diagrams of the structure of 4-phenylbutyrate and the sodium salt of 4-Phenylbutyrate, a known compound, although its formulation as a targeted medication is novel.

Figures 2A and 2B are a set of charts showing the effects of topical sodium phenylbutyrate (1, 5 and 15 mM) on preventing intraocular pressure elevation in a steroid-induced glaucoma model in rabbits.

Figure 3 is a diagram showing the effect of 1 mM topical sodium phenylbutyrate (PB) in reducing the elevated intraocular pressure (IOP) from steroid-induced IOP rise in rabbits.

Figure 4 is a set of charts showing Trimethylamine N-oxide (TMAO), a chemical chaperone that had no effect in the lowering of steroid-induced intraocular pressure (IOP) rise in rabbits.

Figure 5 is a chart showing the effective concentration of sodium phenylbutyrate in preventing steroid-induced IOP rise.
Figure 6 is a chart showing the effect of application frequency of topical sodium phenylbutyrate on preventing steroid-induced IOP rise.

Figure 7 is a diagram showing the long-lasting pharmacodynamic effect of sodium phenylbutyrate (PB) on preventing steroid-induced IOP rise after cessation of topical application in rabbits.

Figure 8 is a chart on the showing the effect of topical sodium phenylbutyrate on the corneal endothelial cell count of the rabbits.

Figure 9 is a bar-chart showing the effect of sodium phenylbutyrate on cultured human trabecular meshwork cells.

Figures 10A-10D are a set of histological images and a bar chart illustrating that sodium phenylbutyrate reduced steroid-induced trabecular meshwork cell loss.

Figures 11A-11C are a set of histological images showing that sodium phenylbutyrate reduced extracellular matrix deposition caused by steroid in the trabecular meshwork.

Figures 12A-12F are a set of electron microscopy images illustrating the effect of sodium phenylbutyrate in the trabecular meshwork.

DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS

A pharmaceutically acceptable salt of phenylbutyrate, especially sodium phenylbutyrate is suitable for use as a medication for treatment of ocular conditions. A formulation in an appropriate solution or inert carrier may be administered as either a parenteral or an oral preparation and can be prepared in the forms of, for example, ophthalmological preparation, injections (intravenous, or through one of the eye or periocular, intravitreal, subconjunctival, subtenon, peribulbar, retrobulbar, and intracameral), tablet, capsule, powder, granule, solution, and the like. These preparations can be prepared by known techniques by suitably adding known carriers. It is preferably used, among others, as an ophthalmological preparation, particularly preferably as an instillation, and such an ophthalmic preparation may be aqueous eye drop, non-aqueous eye drop, suspension eye drop, emulsion eye drop, eye ointment, and the like. The preparation can be produced by preparation methods known to those skilled in the art as a composition suitable for the dosage form by adding pharmacologically acceptable carriers such as tonicity agents, chelating.
agents, stabilizers, pH modifiers, preservatives, antioxidants, solubilizing agents, and thickening agents, if necessary.

[0031] An ophthalmic preparation is prepared by, for example, dissolving or suspending desired ingredients of the above-mentioned compounds in an aqueous solvent such as sterile purified water or physiological saline or a non-aqueous solvent such as vegetable oil including cottonseed oil, soybean oil, sesame oil, or peanut oil at a predetermined osmotic pressure and subjecting the solution or suspension to sterilization such as sterilization by filtration. When a salve or an eye ointment is prepared, an ointment base can be added in addition to the above-mentioned various ingredients. The above-mentioned ointment base is not particularly limited, but preferred examples thereof include oily bases such as petroleum jelly, liquid paraffin, and polyethylene, emulsion bases obtained by emulsifying the oil phase and the aqueous phase with a surfactant or the like, water-soluble bases comprising hydroxypropylmethylcellulose, carboxymethylcellulose, polyethylene glycol or the like.

[0032] It is known that the allosteric conversion from rabbit to human, based on plasma concentrations and calculation, is a factor of 1.9. If the applications including topical eyedrops, lotion, cream and others do not follow the allosteric conversion, the concentration identified to be effective in the animal models will be the same as in human patients. If they follow allosteric conversion, as well as systemic administration like oral, skin patch, or injections including subcutaneous, intramuscular and intravenous administrations, the calculated concentration may need to be adjusted by a factor of 1.9 higher for the plasma levels. Assuming that the plasma levels are the same as that of the target tissue level, the reverse conversion factor may be applied for the calculated doses applicable to humans.

[0033] There are experimental data collected from our own experiments using an animal model of steroid induced glaucoma in rabbits showing the safety and effectiveness of a particular salt of sodium phenylbutyrate, the sodium phenylbutyrate, in preventing intraocular pressure rise and treating the elevated intraocular pressure. Dexamethasone, a commonly used steroid was used in all our experiments. Specifically Figure 2A and 2B are charts that illustrate the effect of sodium phenylbutyrate on preventing intraocular pressure (IOP) rise in a steroid-induced glaucoma model. Herein, nine 7-week-old male New Zealand albino rabbits were randomly divided into 3 groups and each of them received Dexamethasone (Dex) (MaxiDex containing 0.1% Dex, Alcon) 5 times a day in both eyes. In addition, topical sodium phenylbutyrate (PB) (Triple Crown America/ TriButyrate, Inc. Perkasie, PA) in concentrations of 1, 5 or 15 mM were applied to their right eyes 5 times a day and a balanced salt solution (BSS), a physiological saline that acted as a control, to their left eyes 5 times a
day. Intraocular pressure (IOP) was measured twice a week at an interval of 3-4 days by a masked technician. (A) IOP rise was observed after topical Dex had been applied to the left eyes (diamond line: Dex+BSS). Three time points (days 14, 37 and 53) were chosen for data analysis. Time point 1 (day 14) was a commonly adopted time point to obtain significant steroid-induced IOP rise; time point 2 (day 37) showed a maximum reduction of IOP rise; and time point 3 (day 53) was the time when the study ended. The mean baseline intraocular pressure (IOP) was 11.5 mmHg for both eyes. The percentage of reduction in IOP rise by PB was defined as ("Mean IOP rise in eyes with Dex+BSS" minus "Mean IOP rise in eyes with Dex+PB") divided by "Mean IOP rise in eyes with Dex+BSS" x 100%.

[0034] By referring to Figure 2A, the application of phenylbutyrate (PB) eye drops 5 times a day helped reduce Dex-induced IOP rise regardless of their concentrations. The amount of reduction of IOP rise was similar in all the 3 PB doses (square, triangle, circle lines, respectively) and the data were integrated and analyzed as one group. The percentages of mean reduction in IOP rise were 45.0%, 84.7% and 50.0% at the three time points on days 14, 37 and 53 respectively. Figure 2B charts show the longitudinal profiles of IOP measurements of individual rabbits receiving Dex+BSS (left eye, diamonds line) and Dex+PB (right eye, squares line) respectively. Although chaperones are effective in enhancing protein trafficking and reducing intracellular accumulation of abnormal proteins, all of these animals had the normal myocilin gene and the IOP lowering effect of sodium phenylbutyrate should not be related to the enhanced trafficking of the mutated myocilin gene products. This surprising result has led to further investigation and characterization of the therapeutic effects of sodium phenylbutyrate.

[0035] On day 56 when Phase II of the experiment started, topical sodium phenylbutyrate (1 mM), instead of balanced salt solution, was applied to the left eyes of 5 rabbits (Figure 3). The IOP was reduced from 20.5 mmHg on day 56 to 16.6 mmHg on day 67 (Figure 3, brown line), representing a 19% reduction in IOP over a treatment period of 11 days. Moreover, the IOP level of 16.6 mmHg was very close to the mean IOP level of 15.4 mmHg on day 67 (Figure 3, gray line) in the eyes that had been treated with PB in the concentration of 1 mM throughout both phases of the study. It is surprising to have the following observations: (1) as shown in Figures 2A and 2B, sodium phenylbutyrate is effective in preventing an increase in IOP associated with steroid eye-drop use (Phase I, treatment with sodium phenylbutyrate versus control, balance salt solution); and (2) as shown in Figure 3, sodium phenylbutyrate is effective in lowering the IOP, as illustrated by the digression after check point A (Figure 3, brown line).
Figure 4 shows the negative results of Trimethylamine N-oxide (TMAO), a chemical chaperone, in lowering steroid-induced intraocular pressure (IOP) rise in rabbits. Fourteen 7-week-old male New Zealand albino rabbits received topical dexamethasone (Dex) (MaxiDex containing 0.1% Dex, Alcon) 4 times a day in both eyes. Topical trimethylamine N-oxide (TMAO) with concentrations ranging from 2 mM to 300 mM was applied to the right eye whereas balanced salt solution (BSS), a physiological saline that acted as a control, was applied to the left 4 times a day. All rabbits showed an increase in intraocular pressure (IOP) of up to 6 mmHg on day 14 compared with the baseline (day 0). TMAO did not prevent Dex-induced IOP rise for the entire study period of 18 days. The IOP in both eyes which were treated with Dex+BSS (left eyes, blue lines) and Dex+TMAO (right eyes, magenta lines) respectively showed no significant difference. This suggests that prevention of steroid-induced IOP rise by phenylbutyrate is probably not related to chemical chaperone activity.

Figure 5 illustrates the effective concentration of sodium phenylbutyrate in the prevention of steroid-induced intraocular pressure (IOP) rise. The right eyes of 18 rabbits, which were characterized as strong responders as they showed a >30% rise in steroid-induced intraocular pressure (IOP) from the baseline level on day 14, received topical dexamethasone (Dex, MaxiDex, Alcon) and sodium phenylbutyrate (PB) (0.01, 0.1, 0.5, 1.5 and 15 mM) eye drops 5 times a day respectively. Their left eyes were treated with Dex+BSS. The IOP was measured twice a week. The percentage of reduction in IOP rise by PB was calculated based on the formula defined in [0035]. The diagram showed the percentages of reduction in IOP rise (diamonds) on day 14 with respect to the different dosages of PB (x-axis). The mean percentage of the reduction in IOP rise within the groups of different dosages of PB was represented by the (horizontal line). A dose-related reduction in steroid-induced IOP rise by PB was observed. For PB applied at doses varying from 0.1 to 1 mM, the reduction in steroid-induced IOP rise was between 59.7% and 74.9%. Other test doses showed a reduction of about 50%.

Figure 6 illustrates the frequency-related effect of topical sodium phenylbutyrate (PB) on reducing steroid-induced intraocular pressure (IOP) rise. The right eyes of 43 rabbits received topical Dex+PB (0.5 mM) ranging from 1 to 6 times a day. The left eyes received Dex+BSS. IOP was measured twice a week. On day 14, the reduced IOP of individual eyes treated with Dex+PB was compared with the IOP of the contralateral eyes treated with Dex+BSS to obtain a percentage of IOP reduction (diamonds) and the mean percentage of IOP reduction within the group as represented by the (horizontal lines). The mean
percentage of reduction in IOP was calculated based on the very same formula defined in [0036]. It was found that the mean percentage of reduction in IOP increase was highest (74.9%) in the eyes to which PB was applied 5 times a day. The corresponding percentages were 57.9%, 54.4% and 13.2% for eyes to which PB eye drops were applied 4, 2 and 1 time(s) a day respectively.

[0039] The effective concentration of sodium phenylbutyrate to be used topically in the compound ranges from 0.01 mM to 15 mM (Figures 2A and 2B and 5) and should be applied topically from 2 to 5 times a day (Figure 6).

[0040] Figure 7 shows the long-lasting pharmacodynamic effect by sodium phenylbutyrate (PB) on preventing steroid-induced IOP rise after cessation of topical application in rabbits. Eight rabbits were studied in this experiment. All their left eyes received Dex+BSS 5 times a day, from day 0 to day 60, the day when the experiment ended (squares line for both Phase I and Phase II). A significant IOP rise was observed in the first 10 days and the mean IOP from day 10 to day 60 was maintained at a level between 20 and 22 mmHg. The right eyes of 3 randomly-chosen rabbits were treated with Dex+PB (sodium phenylbutyrate, 0.5 mM) eye drops 5 times a day, from day 0 to day 42. IOP measurement showed a lessened Dex-induced IOP rise (solid brown line in Phase I), which was similar to previous observations. The IOP increase slowly in the first 10 days, and from day 10 to day 42, the mean IOP was maintained at a low level between 14 and 16 mmHg. On day 43, the treatment of the right eyes of the 3 rabbits changed from Dex+PB to topical Dex+BSS. Still, Dex+BSS eye drops were applied 5 times a day, until day 60 when the experiment ended (broken brown line in Phase II). With the cessation of topical PB, it was originally expected that the IOP would rise significantly and catch up with the IOP level in the left eyes, where no PB was applied (squares line), in about 10 days. Surprisingly, only a very mild increase in IOP by less than 2 mmHg was observed and the mean IOP level was maintained at about 16.5 mmHg. On day 60 when the experiment ended and the eyes had received treatment of Dex for 18 days), the IOP was stabilized at a level of 16.6 mmHg.

[0041] No adverse ocular or systemic effects were found with regard to the application of sodium phenylbutyrate to the rabbit eye. Specifically, there was no evidence of conjunctival hyperemia, corneal epithelial erosion and/or endothelial cell loss after topical application of sodium phenylbutyrate. Adult male rabbits (n=13) received topical sodium phenylbutyrate (1 and 5 mM) 4 times a day in both eyes. They were examined 3 times a day and none of them exhibited diarrhea, paralysis, convulsions/seizures, bleeding and/or death during the 7-day post-treatment study period. The rabbit eyes were examined by an ophthalmologist on days 7
and 14 in which the rabbits were anesthetized with intramuscular injection of ketamine (75 mg/kg) and xylazine (7.5 mg/kg). No ocular surface (conjunctiva and cornea) diseases such as hyperemia, swelling, inflammation, ulcers and/or bleeding were identified after treatment with PB. Slit lamp biomicroscopy with fluorescein staining did not reveal any defects in the conjunctiva or the cornea. The diagram shows that PB did not cause any significant change in corneal endothelial cell density, as measured by specular microscopy (Figure 8).

[0042] No cytotoxic effect of sodium phenylbutyrate (0.5 and 1 mM) to the cultured human trabecular meshwork (TM) cells was identified (Figure 9). In these tests, cultured human TM cells (7000 cells/ml) were plated in each well in Dulbecco's Modified Eagle medium (DMEM) supplemented with 1000 mg/L glucose, 2% charcoal-stripped fetal bovine serum and antibiotics. They were treated with sodium phenylbutyrate (PB) (0.5, 1 and 5 mM), dexamethasone (Dex) (100 and 500 nM) and a combination of both for 5 days. Using the 3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide dye (MTT) cell viability/proliferation assay (Invitrogen), the formazan intensity was measured with a multiplate reader at an excitation wavelength of 595 nm and an emission wavelength 610 nm. The mean signal intensity was expressed as a percentage and was compared to the untreated control among treatments. It was found that PB in the concentrations of 0.5 mM and 1 mM was not cytotoxic to the trabecular meshwork cells. Similar results were found for Dex in concentrations of 100 nM and 500 nM.

[0043] Figures 10 and 11 illustrate the structural and anatomical changes in the trabecular meshwork (TM) that provide possible explanation for why sodium phenylbutyrate is able to treat and prevent IOP rise. High IOP is a key feature in glaucoma and partial blockage of the aqueous outflow in the TM is a key reason. When the aqueous outflow passes the drainage openings, the TM cells in the region act as scavengers to clear the debris/deposition which will otherwise block the pathway and hence, resulting in a rise in IOP. While steroid has been shown to damage the TM cells (Figure 10D) and thus, increase deposition (Figure 11B) in the aqueous drainage pathway in the TM that will lead to an increase in IOP, PB has been shown in our experiment to reduce the loss of TM cell (Figure 10D) and maintain a more patent pathway (Figure 11C) for aqueous drainage.

[0044] In relationship to Figure 10, sodium phenylbutyrate was shown to be able to reduce dexamethasone-induced TM cell loss. The cell density in the TM aqueous outflow region was examined using the Dex and Dex+PB treated rabbit eyes. After topical application of sodium phenylbutyrate (PB) for 14 days, the rabbits were sacrificed. The specimens were paraffin-processed and serially sectioned at a thickness of 5 µm for hematoxylin-eosin histochemistry.
Sections of (A) untreated control; (B) treated with Dex, 0.1% for 14 days; and (C) treated with Dex + PB in a concentration of 0.5 mM for 14 days are shown. The number of cells in TM region was quantified and area was measured by Image J software (NIH, US). (D) The cell densities (mean ± standard deviation) were compared among the control and treatment groups and P values were calculated by unpaired Student’s t-test. In TM region beneath the scleral plexus of veins, a reduction of cell density by 53% was found after treatment with Dex. Such cell loss was reduced by the addition of topical PB in the treatment process. A dose-related correction was found with concentrations varying from 0.02 to 0.5 mM. The percentages of cell loss were 39% for PB in the concentration of 0.02 mM, 31% for PB in the concentration of 0.1 mM and 26% for PB in the concentration of 0.5 mM. These results indicate that PB could reduce the TM cell density reduction induced by steroid (0.1 % Dex in this study). With a lesser degree of TM cell loss, the TM aqueous outflow region could be maintained more patent and hence prevent or lessen the steroid-induced intraocular pressure rise.

**Figure 11A-11C** illustrates that sodium phenylbutyrate can reduce the extracellular matrix deposition in the aqueous outflow channels in the trabecular meshwork. The steroid-induced intraocular pressure (IOP) rise is secondary to an increased resistance of aqueous outflow, which arises from accumulation and/or deposition of substances such as glycogen and collagen in the extracellular matrix of the trabecular meshwork. An experiment was conducted to determine whether sodium phenylbutyrate (PB) could reduce the amount of glycogen and collagen accumulated in the extracellular matrix of the trabecular meshwork. The extracellular protein and collagen substrate deposited on paraffin sections of TM aqueous outflow region were examined in Dex treated and Dex + PB treated rabbit eyes by special periodic acid-Schiff and Masson trichrome histochemical staining. The rabbit eyes were paraffin-processed and serially sectioned at a thickness of 5 µm for histochemistry. Sections of (A) untreated control; (B) treated with Dex (0.1%) for 14 days and (C) treated with Dex (0.1%) + PB (0.5 mM) for 14 days are shown. On the paraffin sections of the rabbit eyes with topical dexamethasone with or without sodium phenylbutyrate (1 mM) for 14 days, periodic acid-Schiff histochemical staining (**Figure 11, middle column**) demonstrated greater deposition of glycogen (in purple-magenta color) was found in the intercellular space of the dexamethasone-treated trabecular meshwork region (**Figure 11B middle**) while the glycogen deposition was greatly reduced in the eyes treated with dexamethasone and sodium phenylbutyrate (1 mM, 14 days) (**Figure 11C middle**). This reduced level resembled that found in the untreated control eyes (**Figure 11A middle**). For sections with Masson
trichrome histochemical staining (Figure 11, right column), collagen deposit (appeared in green color) was substantially increased in the dexamethasone-treated trabecular meshwork region (Figure 11B right) when compared with the untreated control (Figure 11A right). This indicates a possible blockage of aqueous outflow which might lead to a steroid-induced intraocular pressure rise. Reduced collagen stain was noted in the dexamethasone and sodium phenylbutyrate-treated trabecular meshwork region (Figure 11C right). With lesser amount of extracellular matrix deposition in eyes treated with PB, there will be better aqueous drainage and hence, resulting in a lower IOP.

[0046] Figures 12A-12F show electron microscopy of the trabecular meshwork (TM) of rabbit eyes. The ultrastructural morphology of rabbit trabecular meshwork (TM) tissues was examined in untreated control eyes, dexamethasone (Dex) (0.1%) treated eyes and Dex + PB (1 mM) treated eyes by transmission electron microscopy. In the control TM region, clear extracellular matrix region was observed in the open aqueous outflow channels. The normal rabbit trabecular meshwork is shown in Figures 12A and B. It consists of bundles of fine fibers (elastic and collagen fibers) of the trabecular cells (Figure 12A). Very rarely, extracellular matrix plaques were observed in this region. At higher magnification, various subcellular organelles, including the nucleus, rough endoplasmic reticulum and mitochondria, appeared normal and without morphological defects (Figure 12B). In the trabecular meshwork of rabbit eyes treated with topical 0.1% dexamethasone for 42 days, there was deposition of electron dense materials (Figure 12C). At higher magnification, the cells contained enlarged cisternae of rough endoplasmic reticulum and there were sheaths of basement membrane-like material located in the intercellular space (Figure 12D). Some nuclei appeared to have more heterochromatin, indicating low cell activity. The deposition was not apparent when there was concurrent topical application of 1 mM sodium phenylbutyrate for 48 days (Figure 12E). A reduction in extracellular matrix plaques among the trabecular fiber bundles was observed. The outflow channel was clear and was similar to that in the control eyes. At higher magnification, the rough endoplasmic reticulum appeared to be normal and without dilatation (Figure 12F). Other organelles, such as mitochondria and nucleus, appeared normal as well.

[0047] The invention may be characterized as a method for prevention and treatment of conditions of the eye, namely ocular hypertension and primary glaucoma, with a pharmacetically acceptable compound containing 4-phenylbutyrate sufficient to impede intraocular pressure elevation and/or treat glaucoma. More specifically it may be used for reducing intraocular pressure in patients with ocular hypertension and secondary glaucoma,
also for the condition of steroid-induced elevation of intraocular pressure and secondary glaucoma.

[0048] The method includes administering the compound through topical application to the eye through one of eye drops, eye lotion, and eye cream, and alternatively, the compound is administrated through one of subconjunctival, subtenon, anterior chamber and intravitreal injection, or wherein the compound is administrated one of orally, through skin patches and systemically through injections.

[0049] The concentration of sodium phenylbutyrate to be used topically in the compound ranges from 0.01 mM to 15 mM its topical application frequency ranges from one to five times a day.

[0050] The compound may be a metabolite of sodium phenylbutyrate, including but not limited to phenylacetate and acetylglutamine or a prodrug of sodium phenylbutyrate or the like salt of phenylbutyrate. The concentration of any of the metabolites of the salt of phenylbutyrate to be used in the compound is the equivalent of the concentration of the salt of phenylbutyrate.

[0051] Salts of phenylbutyrate can be formulated for controlled or sustained release with a more convenient dosing.

[0052] The phenylbutyrate salt, particularly sodium phenylbutyrate, exerts its biological activity in reducing intraocular pressure rise in conjunction with sympathetic nerve stimulants (nonselective stimulants such as epinephrine and alpha2 stimulants such as apraclonidine), sympathetic nerve blockers (beta blockers including timolol, befunolol, carteolol, npradilol, betaxolol, levobunolol, and metipranolol and alpha 1 blockers such as bunazosin hydrochloride), parasympathetic nerve agonists (pilocarpine), carbonic anhydrase inhibitors (acetazolamide and dorzolamide), prostaglandin analogue (isopropyl unoprostone, latanoprost, travoprost, bimatoprost), and cortisol-derived compounds, and the like.

[0053] The phenylbutyrate salt, its metabolites, or prodrugs can be formulated with anti-inflammatory steroid in eye-drops, injection, controlled or sustained release methods such as in slow-release drug implant, or impregnated in degradable material formats (subconjunctival, subtenon, intracameral (injecting into the anterior chamber of the eye), or intravitreal) to prevent and treat the steroid-induced increase in intraocular pressure.
[0054] The invention has been explained with reference to specific embodiments. Other embodiments will be evident to those of skill in the art. It is therefore not intended that the invention be limited, except as indicated by the appended claims.
WHAT IS CLAIMED IS:

1. A medication for use in treatment of disease comprising:
   an effective amount of a compound in a carrier, wherein the compound is a
   pharmaceutically acceptable salt or metabolite or prodrug containing 4-phenylbutyrate, for
   use to impede intraocular pressure elevation.

2. The medication according to claim 1, wherein the carrier with said
   compound is in form suitable for topical application to eyes through one of eye drops, eye lotion and
   eye cream.

3. The medication according to claim 1, wherein said compound is in form
   administered through one of eye and periocular injections, including one of subconjunctival, subtenon, peribulbar, retrobulbar, and anterior juxtascleral depot; and intraocular injections
   including one of intracameral and intravitreal injections.

4. The medication according to claim 1, wherein the carrier with said
   compound is in oral or parenteral form, either for use alone or in augmentation with other
   medications, including topical use or periocular injections, in form suitable for topical
   application to eyes through one of eye drops, eye lotion and eye cream, or in form administered
   through one of eye and periocular injections, including one of subconjunctival, subtenon, peribulbar, retrobulbar, and anterior juxtascleral depot; and intraocular injections including
   one of intracameral and intravitreal injections, to augment overall and long term beneficial
   effect through increasing systemic drug level.

5. The medication according to claim 1, wherein concentration of the
   phenylbutyrate salt or the metabolite or the prodrug to be used topically in said compound is
   an equivalent of phenylbutyrate salt concentration range from 0.01 mM to 15 mM.

6. The medication according to claim 1, wherein the compound including
   metabolites is formulated with one of an anti-inflammatory steroid and a steroid prodrug in
   form suitable in one of for application eyes and for systemic application including one of oral
   ingestion and parenteral routes administration to prevent and treat the steroid-induced
   increase in intraocular pressure, the application including one of the group including:
   topical application, including eye drops, eye lotion and eye cream;
   injectable fluids in form administered through eye and periocular injections, including one of subconjunctival, subtenon, peribulbar, retrobulbar, and anterior juxtascleral
   depot;
7. A method for treatment of a human patient comprising:
administering an effective amount of a compound in a carrier to the human
body, wherein the compound is a pharmaceutically acceptable salt containing 4-
phenylbutyrate, to impede intraocular pressure elevation and treat for glaucoma in the human
patient.

8. The method according to claim 7, wherein said compound is administered
through topical application to eyes through one of eye drops, eye lotion and eye cream.

9. The method according to claim 7, wherein said compound is administered
through one of eyes and periocular injections, including one of subconjunctival, subtenon,
peribulbar, retrobulbar, and anterior juxtascleral depot; intraocular injections including one of
intracameral and intravitreal injections; and systemic application including one of oral
ingestion and parenteral routes administration.

10. The method according to claim 8, wherein a concentration of
phenylbutyrate salt or sodium phenylbutyrate to be used topically in said compound ranges
from 0.01 mM to 15 mM and applied topically one to five times a day.

11. The method according to claim 7, wherein the compound is a prodrug
or a metabolite of phenylbutyrate salt in an equivalent of phenylbutyrate salt concentration of
0.01 mM to 15 mM and applied topically one to five times a day.

12. The method according to claim 7, wherein the phenylbutyrate salt is
operative to exert biologic activity in reducing rise of intraocular pressure in conjunction with one of
sympathetic nerve stimulants, sympathetic nerve blockers, parasympathetic nerve agonists,
carbonic anhydrase inhibitors, prostaglandin analogues and cortisol-derived compounds.

13. The method according to claim 7, wherein the phenylbutyrate-salt-
containing compound including metabolites is formulated with an anti-inflammatory steroid
or a steroid prodrug in form suitable for topical application to eyes through one of eye drops,
eye lotion and eye cream; and in form administered through one of eye and periocular
injections, including one of subconjunctival, subtenon, peribulbar, retrobulbar, and anterior
juxtascleral depot; intraocular injections including one of intracameral and intravitreal
injections; and systemic application including one of oral ingestion and parenteral routes
administration to prevent and treat steroid-induced increase in intraocular pressure.

14. The method according to claim 7, phenylbutyrate-salt-containing
compound including metabolites is formulated with an anti-inflammatory steroid or a steroid
prodrug for controlled or sustained release with an appropriate dosing.
FIGURES 1A and 1B

Time point: 1 2 3

A

B

FIGURES 2A and 2B
- Left eyes (n=3): Dex + BSS from day 0 to 67
- Left eyes (n=5): Dex + BSS from day 0 to 55; Dex + PB (1 mM) from day 56 to 67
- Right eyes (n=3): Dex + PB (1 mM) from day 0 to 67

FIGURE 3
**FIGURE 5**

**FIGURE 6**
**FIGURE 7**

![Graph showing IOP levels over time for different treatment groups.]

- Left eyes (n=8): Dex + BSS from day 0 to 60
- Right eyes (n=3): Dex + PB (0.5 mM) from day 0 to 42
- Right eyes (n=3): Dex + BSS from day 43 to 60

**FIGURE 8**

![Bar chart showing endothelial cell count for different treatment groups.]

- Left eyes
- Right eyes
FIGURE 9

**Hematoxylin-eosin**

**A**
Untreated control

**B**
Dex (0.1%)
14 days

**C**
Dex +
PB (0.5 mM)
14 days

**D**

**FIGURES 10A – 10D**
FIGURES 11A – 11C

FIGURES 12A – 12F
INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 11/34158

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A01N 37/10; A61K 31/19 (201 1.01)
USPC - 514/570

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

USPC - 514/570

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 424/94.4; 514/77, 311, 561, 569, 678 (see search terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWEST (PGPB, USPT, EPAB, JPAB); Google (Google Scholar, Google Patents)

Search Terms Used: 4-phenylbutyrate, 4-phenylbutyrate, 4-phenyl butyrate, 4-phenyl butanoate, 4-phenyl butanoate, 4-phenyl butanoate, glaucoma, ocular hypertension, intraocular pressure, ocular, intraocular, hypertension, pressure, eye disorder

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X - Y</td>
<td>US 2008/0300292 A1 (LETTS et al.) 04 December 2008 (04.12.2008) para [0006], [0008], [0012], [0014], [0021], [0376], [0439]-[0440], [0432]-[0433], [0443], [0452]; claims 1-2, 7-8</td>
<td>1-3, 6-9, 12-14, 10-11</td>
</tr>
<tr>
<td>X - Y</td>
<td>US 2007/0027094 A1 (SINGH) 01 February 2007 (01.02.2007) para [0034], [0043]-[0045], [0048], [0175], [0186], [0188], [0200]-[0201], [0206] Table 1 *</td>
<td>1-2, 4-5, 10-11</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search 27 June 2011 (27.06.2011)

Date of mailing of the international search report 08 JUL 2011

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-1881

Authorized officer: Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

Form PCT/ISA/210 (second sheet) (July 2009)